| 3 | Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. (Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR) Blood 2011 Feb 10;117(6):e67-74 103 Citations |
| 4 | Von Willebrand disease in the United States: perspective from the Zimmerman program. (Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL, Zimmerman Program Investigators) Ann Blood 2018 Jan;3 |
| 2 | Molecular pathogenesis and heterogeneity in type 3 VWD families in U.S. Zimmerman program. (Christopherson PA, Haberichter SL, Flood VH, Perry CL, Sadler BE, Bellissimo DB, Di Paola J, Montgomery RR, Zimmerman Program Investigators) J Thromb Haemost 2022 Jul;20(7):1576-1588 18 Citations |
| 1 | Robert D. Zimmerman, MD. (Russell E, with contributions from Drs, Mathews V, Tsiouris J, Wood C, Naidich T) AJNR Am J Neuroradiol 2023 Dec 11;44(12):E52-E53 |
| 1 | Effect of age on ISTH-BAT scores and low VWF diagnosis in the Zimmerman Program. (Atiq F, Christopherson PA, Doherty D, Hulshof AM, Haberichter SL, Flood VH, Lavin M, O'Connell NM, Ryan K, Byrne M, Grabell J, James PD, Lillicrap D, Montgomery RR, Di Paola J, O'Donnell JS) Blood Adv 2025 Oct 14;9(19):4780-4789 4 Citations |
| 1 | Heavy Menstrual Bleeding and Hormonal Therapy in Women with Type 1 von Willebrand Disease Enrolled on the Zimmerman Program. (Machin N, Navarrete A, Rothenberger S, Flood V, Christopherson P, Montgomery R, Ragni MV, Zimmerman Program Investigators) Clin Appl Thromb Hemost 2025;31:10760296251359294 |
